Key Highlights
- OS Therapies reached regulatory consensus with European agencies on an adaptive Phase 3 framework evaluating OST-HER2.
- The trial targets resected pulmonary metastatic osteosarcoma.
- Clinical trial startup is enabled during the fourth quarter of 2026.
- A pre-BLA Type B discussion is scheduled for late 2026, supported by MHRA Leadership within Project Orbis.
OS Therapies Incorporated (NYSE: OSTX) reached regulatory consensus alongside European agencies regarding its adaptive Phase 3 framework evaluating OST-HER2 for resected pulmonary metastatic osteosarcoma.
Company Overview
OS Therapies is a clinical-stage biopharmaceutical company focused on developing therapies for osteosarcoma, a rare and aggressive form of bone cancer that predominantly affects children and young adults. Its lead candidate, OST-HER2, is a listeria-based immunotherapy designed to stimulate an immune response against HER2-expressing tumor cells, targeting a patient population with limited existing treatment Options following metastatic recurrence.
The company has pursued an international regulatory strategy for OST-HER2, engaging with both U.S. and European regulators, including through Project Orbis, a framework that allows for concurrent review of oncology products across multiple international regulatory agencies, an approach intended to accelerate the path toward global approvals for a rare pediatric and young-adult cancer indication.
What Happened
The alignment enables clinical trial startup during the fourth quarter of 2026, with a pre-BLA Type B discussion scheduled for late 2026 as the firm seeks accelerated global approvals, supported by MHRA leadership within Project Orbis.
Market Reaction
The disclosed information does not include stock price or trading data for OS Therapies following the regulatory consensus announcement.
Outlook
The planned fourth-quarter 2026 clinical trial startup and the late-2026 pre-BLA Type B discussion represent the next major disclosed milestones for OST-HER2 as the company pursues accelerated global approval pathways.






Please wait processing your request...